A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
- Registration Number
- NCT05997485
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to collect information on the:
* general information of a group of people such as their age, sex, and other facts.
* clinical information of the patients such as any other illness before having COVID 19.
In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.
This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.
This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.
The study will include patient information of those who:
* are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.
* are 18 years of age or older.
* are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June 2023
- Nirmatrelvir, ritonavir written prescription
- There are no exclusion criteria for this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Participants receiving Paxlovid Treatment Nirmatrelvir/Ritonavir Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
- Primary Outcome Measures
Name Time Method Clinical Characteristics of Participants Approximately 01 June 2022 through 30 June 2023 Demographical Characteristics of Participants Approximately 01 June 2022 through 30 June 2023 Number of Participants with Pre-existing Comorbidities Approximately 01 June 2022 through 30 June 2023
- Secondary Outcome Measures
Name Time Method